Loading
A phase 2 trial of Inotuzumab ozogamicin in acute lymphoblastic leukaemia, run by Pfizer, now recruiting.
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL is a phase 2 interventional study registered as NCT05748171 by Pfizer, with 100 participants planned, started 2023-05-17 and due to reach its primary completion in 2033-05-21. Interventions recorded: Inotuzumab ozogamicin and ALLR3.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/